Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
Deal charges, not weaker sales, made the loss
One acquired-research charge exceeded the entire pre-tax loss, so the quarter's red ink reflects buying pipeline, not selling less.
For investorsWhat Biogen's profit depends on once the deal costs pass
For foundersBuying growth versus building it: the trade-offs behind Biogen's deals
Royalties and profit shares on Roche's antibodies outearn every Biogen product, yet the line barely grew from a year earlier.
Syfovre, acquired with Apellis, now sells about as much as Vumerity, Biogen's largest oral MS drug, helping fill the gap generics open.
Free cash flow stayed positive through a net loss, because the largest charges were non-cash or counted as investing outflows.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Biogen from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
